Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Lupus Nephritis Market Set To Climb From $2.24 Billion In 2026 To $2.98 Billion By 2030
The lupus nephritis market has shown robust expansion in recent times. Forecasts indicate it will expand from $2.08 billion in 2025 to $2.24 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 7.7%. Historically, this growth has been driven by factors such as the rising incidence of systemic lupus erythematosus, advancements in kidney biopsy and diagnostic methodologies, the extensive application of corticosteroids for treatment, an expansion in hospital-centric nephrology services, and a heightened understanding of autoimmune kidney conditions.
The lupus nephritis market is anticipated to experience robust expansion over the next few years. It is forecast to attain a value of $2.98 billion by 2030, growing at a compound annual growth rate (CAGR) of 7.4%. This projected growth in the upcoming period stems from factors such as increasing investment in biologic drug development, a heightened focus on early intervention to prevent kidney failure, wider adoption of combination therapy regimens, the enlargement of specialty nephrology clinics, and a rise in healthcare spending directed towards autoimmune disease management. Significant trends during the forecast period encompass an increasing emphasis on early diagnosis and continuous disease monitoring, the expanding use of immunosuppressive and biologic therapies, a greater focus on personalized treatment approaches, the extension of long-term disease management strategies, and heightened awareness of autoimmune kidney complications.
Get A Free Sample Report With In-Depth Market Insights:
Lupus Nephritis Market Growth Catalysts And Demand Drivers
The rising incidence of genetic predisposition is anticipated to drive expansion in the lupus nephritis market. This term describes inherited genetic characteristics that heighten an individual’s susceptibility to specific diseases or conditions. The growing occurrence of genetic predisposition stems from elements like inheritance patterns, environmental factors, and specific gene mutations. The escalating presence of genetic predisposition is crucial in the onset of lupus nephritis, highlighting the influence of inherited genetics in autoimmune conditions, especially those impacting renal function. As an illustration, data from October 2024 by the Cystic Fibrosis Trust, a UK national charity, showed the UK CF Registry had 11,148 registered patients in 2022, rising to 11,318 in 2024, indicating a 1.52% increase in those with cystic fibrosis (CF). Consequently, the expanding prevalence of genetic predisposition is fueling the growth of the lupus nephritis market.
Lupus Nephritis Market Segment Landscape And Growth Outlook
The lupus nephritis market covered in this report is segmented –
1) By Stage: Class 1, Class 2, Class 3, Other Stages
2) By Drug Class: Immunosuppressive Drugs, Corticosteroids, Biological Agents, Antimalarial Drugs
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
5) By End-User: Hospitals, Specialty Clinics, Other End-Users
Subsegments:
1) By Class 1: Asymptomatic Cases, Mild Proteinuria, Incidental Diagnosis
2) By Class 2: Mild Hematuria, Low-Grade Proteinuria, Minimal Immune Complex Deposition
3) By Class 3: Active Lesions, Chronic Sclerotic Lesions, Crescent Formation
4) By Other Stages: Class 4 (Diffuse Lupus Nephritis), Class 5 (Membranous Lupus Nephritis), Class 6 (Advanced Sclerotic Lupus Nephritis)
Lupus Nephritis Market Trends Shaping Long-Term Demand
Leading companies in the lupus nephritis market are directing their efforts towards the development of advanced second-generation calcineurin inhibitors to improve treatment efficacy and long-term kidney outcomes for patients. These second-generation calcineurin inhibitors are utilized in lupus nephritis to mitigate inflammation and prevent kidney damage through the modulation of immune responses. For example, in September 2024, Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company based in Canada, announced that the Japanese Ministry of Health, Labour, and Welfare had granted approval for LUPKYNIS (voclosporin) for the treatment of lupus nephritis. This approval permits voclosporin to be administered in conjunction with mycophenolate mofetil (MMF), a decision supported by data from the AURORA Clinical Program, which demonstrated its safety and efficacy. The approval signifies a major milestone, expanding therapeutic options for lupus nephritis patients in Japan and contributing to improved disease management and patient outcomes.
Lupus Nephritis Market Competitive Landscape: Who Leads The Industry?
Major companies operating in the lupus nephritis market are F Hoffmann La Roche Ltd, Bristol Myers Squibb, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca PLC, Pfizer Inc, Johnson and Johnson, Merck and Co Inc, Sanofi, AbbVie Inc, Bayer AG, Amgen Inc, UCB SA, Otsuka Pharmaceutical Co Ltd, Aurinia Pharmaceuticals Inc, RemeGen Co Ltd, Kezar Life Sciences, Equillium Inc, Kyverna Therapeutics Inc, Biogen Inc
View The Full Lupus Nephritis Market Report:
Lupus Nephritis Market Regional Analysis And Top Geography
Asia-Pacific was the largest region in the lupus nephritis market in 2025. The regions covered in the lupus nephritis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
